Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study.
Zaballa ME, Perez-Saez J, de Mestral C, Pullen N, Lamour J, Turelli P, Raclot C, Baysson H, Pennacchio F, Villers J, Duc J, Richard V, Dumont R, Semaani C, Loizeau AJ, Graindorge C, Lorthe E, Balavoine JF, Pittet D, Schibler M, Vuilleumier N, Chappuis F, Kherad O, Azman AS, Posfay-Barbe KM, Kaiser L, Trono D, Stringhini S, Guessous I; Specchio-COVID19 study group.
Zaballa ME, et al. Among authors: kaiser l.
Lancet Reg Health Eur. 2023 Jan;24:100547. doi: 10.1016/j.lanepe.2022.100547. Epub 2022 Dec 1.
Lancet Reg Health Eur. 2023.
PMID: 36474728
Free PMC article.